These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 18422634)

  • 41. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
    Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Metformin and pioglitazone: Effectively treating insulin resistance.
    Staels B
    Curr Med Res Opin; 2006; 22 Suppl 2():S27-37. PubMed ID: 16914073
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cardiovascular effects of thiazolidinediones: a review of the literature.
    Acharya D; Falik R
    South Med J; 2009 Jan; 102(1):51-6. PubMed ID: 19077768
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk.
    Derosa G; Maffioli P
    Curr Mol Pharmacol; 2012 Jun; 5(2):272-81. PubMed ID: 22122457
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Thiazolidinedione insulin sensitizers and the heart: a tale of two organs?
    Buckingham RE; Hanna A
    Diabetes Obes Metab; 2008 Apr; 10(4):312-28. PubMed ID: 18333890
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of thiazolidinediones and sulfonylureas in patients with diabetes.
    Derosa G; Maffioli P
    Diabetes Technol Ther; 2010 Jun; 12(6):491-501. PubMed ID: 20470234
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Thiazolidinediones in patients with type 2 diabetes mellitus and heart failure.
    Granberry MC; Hawkins JB; Franks AM
    Am J Health Syst Pharm; 2007 May; 64(9):931-6. PubMed ID: 17468147
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
    Paneni F; Lüscher TF
    Am J Med; 2017 Jun; 130(6S):S18-S29. PubMed ID: 28526186
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Thiazolidinediones.
    Yki-Järvinen H
    N Engl J Med; 2004 Sep; 351(11):1106-18. PubMed ID: 15356308
    [No Abstract]   [Full Text] [Related]  

  • 50. Autonomic neuropathy predisposes to rosiglitazone-induced vascular leakage in insulin-treated patients with type 2 diabetes: a randomised, controlled trial on thiazolidinedione-induced vascular leakage.
    Rennings AJ; Smits P; Stewart MW; Tack CJ
    Diabetologia; 2010 Sep; 53(9):1856-66. PubMed ID: 20499046
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Drug interactions of clinical importance with antihyperglycaemic agents: an update.
    Scheen AJ
    Drug Saf; 2005; 28(7):601-31. PubMed ID: 15963007
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Cardiovascular effects of the thiazolidinedione troglitazone].
    Yamada K; Kuzuya H; Nakano T
    Nihon Rinsho; 2000 Feb; 58(2):435-9. PubMed ID: 10707572
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Review article: Thiazolidinediones and heart failure.
    Chaggar PS; Shaw SM; Williams SG
    Diab Vasc Dis Res; 2009 Jul; 6(3):146-52. PubMed ID: 20368206
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Metabolic and additional vascular effects of thiazolidinediones.
    Martens FM; Visseren FL; Lemay J; de Koning EJ; Rabelink TJ
    Drugs; 2002; 62(10):1463-80. PubMed ID: 12093315
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Glucose-independent impact of the glitazones on the cardiovascular outcome].
    Hanefeld M
    MMW Fortschr Med; 2005 Jan; 147(1-2):37-9. PubMed ID: 15704569
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Heart, diabetes and glitazones].
    Le Feuvre C
    Ann Endocrinol (Paris); 2004 Feb; 65(1 Suppl):S26-35. PubMed ID: 15163921
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
    Thrasher J
    Am J Cardiol; 2017 Jul; 120(1S):S4-S16. PubMed ID: 28606343
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.
    Nesto RW; Bell D; Bonow RO; Fonseca V; Grundy SM; Horton ES; Le Winter M; Porte D; Semenkovich CF; Smith S; Young LH; Kahn R; ;
    Circulation; 2003 Dec; 108(23):2941-8. PubMed ID: 14662691
    [No Abstract]   [Full Text] [Related]  

  • 59. Effects of the thiazolidinedione medications on micro- and macrovascular complications in patients with diabetes--update 2008.
    Rohatgi A; McGuire DK
    Cardiovasc Drugs Ther; 2008 Jun; 22(3):233-40. PubMed ID: 18373186
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The cardiovascular safety of rosiglitazone.
    Ajjan RA; Grant PJ
    Expert Opin Drug Saf; 2008 Jul; 7(4):367-76. PubMed ID: 18613801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.